论文部分内容阅读
为研究~(131)I对甲状腺C细胞的影响,作者对22例曾以~(131)I治疗的甲亢患者的基础降钙素(CT)水平和CT分泌贮备进行了测定。受试者均为女性,其中13例为Graves病,9例为毒性多结节性甲状腺肿,均未经外科治疗。年龄44±11岁,5例为绝经后妇女。接受~(131)I治疗至受试时的间隔44±9月(33～62月)。~(131)I治疗剂量16±7.6m Ci(8～32mCi)。均未服用影响钙代谢的药物,根据有无~(131)I所致甲低和甲状腺肿类型分组。对照组为15例健康妇女,年龄42±11岁,2例为绝经后妇女,未服用激素和影响钙代谢的药物。 于上午8:30～9:30空腹抽取静脉血,检测CT、PTH、T_3、T_4、TSH和血钙。然后将元素
To investigate the effect of ~ (131) I on thyroid C-cells, the authors measured baseline calcitonin (CT) levels and CT secretion reserve in 22 patients with ~ (131) I-treated hyperthyroidism. All subjects were female, of which 13 were Graves’ disease and 9 were multi-nodular goiters without surgical treatment. Age 44 ± 11 years old, 5 cases of postmenopausal women. The interval from treatment of ~ (131) I to trial was 44 ± 9 months (33 to 62 months). ~ (131) I therapeutic dose of 16 ± 7.6m Ci (8 ~ 32mCi). None of the drugs that affected calcium metabolism were classified according to the presence or absence of ~ (131) I and hypothyroidism. Control group of 15 healthy women, aged 42 ± 11 years, 2 cases of postmenopausal women, did not take hormones and drugs that affect calcium metabolism. Venous blood was drawn from 8:30 am to 9:30 am on an empty stomach to detect CT, PTH, T_3, T_4, TSH and serum calcium. Then the element